Monte Rosa Therapeutic (GLUE) Jefferies Global Healthcare Conference 2026 summary

Company overview and pipeline highlights

• Focuses on developing oral molecular glue degraders for immunology/inflammation (I&I) and oncology, with several programs at phase II stage.

• MRT-6160 (VAV1 degrader) out-licensed to Novartis, with multiple phase II programs anticipated as milestones this year.

• MRT-8102 (NEK7 degrader) in proof-of-concept G-FORCE-1 study for cardiovascular risk, showing strong CRP reduction data.

• MRT-2359 (GSPT1 degrader) demonstrated promising results in metastatic castration-resistant prostate cancer with AR mutations; phase II study to start next quarter.

• Next-generation NEK7 molecule in preclinical stage, and CDK2/Cyclin E1 program targeting IND later this year.

Scientific rationale and differentiation

• NEK7 degradation prevents NLRP3 inflammasome assembly, offering sustained inhibition and upstream impact on inflammation compared to targeting IL-1/IL-6.

• Approach may offer efficacy and safety advantages by avoiding complete cytokine depletion, preserving necessary immune functions.

• Molecular glue degraders achieve target degradation across a wide dose range due to catalytic mechanism, potentially reducing off-target risks.

Clinical development and upcoming catalysts

• G-FORCE-1 expanded to four arms (three doses, one placebo) in high cardiovascular risk patients; 40 mg dose showed 85% CRP reduction at week four without rebound.

• Upcoming data will include unblinded safety and additional biomarkers (e.g., IL-6), informing phase II design.

• G-FORCE-2 (ASCVD) will be a three-month CRP study with possible extension, focusing on safety and exploratory endpoints like liver inflammation and weight loss.

• Gout phase II (Q4 or Q1 next year) will assess acute flare and recurrent flare frequency, targeting patients with kidney insufficiency.

• HS phase II leverages high NLRP3 activity in disease, with design informed by recent IL-1 beta antibody data.